Parallax Volatility Advisers
CSTL icon

Parallax Volatility Advisers’s Castle Biosciences CSTL Stock Holding History

Parallax Volatility Advisers’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-75,000
Closed -$5.5M – 3057
2021
Q2 		$5.5M Buy
+75,000
New +$4.95M ﹤0.01% 1162

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
ZCI
Zevenbergen Capital Investments Edmonds, Washington $4.38B AUM 56.68% 1-Year Est. Return

Parallax Volatility Advisers's CSTL Position: Q3 2021 in Review

Parallax Volatility Advisers sold out of Castle Biosciences (CSTL) in Q3 2021, closing a stake of 22 shares — an estimated $2K sold.

Parallax Volatility Advisers first reported a position in CSTL in Q2 2021 and held it in 1 quarter. The position peaked at $2K in Q2 2021. 188 funds tracked by Wall St. Rank hold CSTL as of Q3 2021.

  • Parallax Volatility Advisers reported no remaining Castle Biosciences position as of Q3 2021 after selling out during the quarter.
  • Parallax Volatility Advisers sold 22 Castle Biosciences shares in Q3 2021, an estimated $2K.
  • Parallax Volatility Advisers first reported a position in Castle Biosciences in Q2 2021 and held it in 1 quarter.
  • Parallax Volatility Advisers's Castle Biosciences position peaked at $2K in Q2 2021.
  • 188 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2021.

Based on Parallax Volatility Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.